Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1961-1967

  Li, Ming ^a   Zhang, Qian ^b   Wu, Liang ^c   Jia, Chengyou ^a   Shi, Fuhua ^d   Li, Shaocai ^d   Peng, Aimei ^a   Zhang, Guoliang ^a   Song, Xiaolian ^a   Wang, Changhui ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d Department of Nuclear Medicine Shanghai 10th People's Hospital Tongji University ^*  (China)

Author keywords

Early diagnosis; Lung cancer; MicroRNA; Non invasive biomarker; Prognostic marker

Indexed keywords

MICRORNA; MICRORNA 499; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD ANALYSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

AGED; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84908128992     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3029     Document Type: Article

References (31)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
3. Li M, Zhang Q, Fu P, et al: Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One 7: e37229, 2012.
4. Smith RA, Brooks D, Cokkinides V, et al: Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 63: 88-105, 2013.
5. Goldstraw P, Ball D, Jett JR, et al: Non-small-cell lung cancer. Lancet 378: 1727-1740, 2011.
6. Rami-Porta R and Goldstraw P: Strength and weakness of the new TNM classification for lung cancer. Eur Respir J 36: 237-239, 2010.
7. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
8. van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11: 644-656, 2011.
9. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
10. Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M: microRNAs in cancer management. Lancet Oncol 13: e249-e258, 2012.
11. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
12. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
13. Voortman J, Goto A, Mendiboure J, et al: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70: 8288-8298, 2010.
14. Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726, 2010.
15. Markou A, Sourvinou I, Vorkas PA, et al: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 81: 388-396, 2013.
16. Vinci S, Gelmini S, Pratesi N, et al: Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med 49: 2073-2080, 2011.
17. Kroh EM, Parkin RK, Mitchell PS and Tewari M: Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298-301, 2010.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001.
19. Peltier HJ and Latham GJ: Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852, 2008.
20. Ruopp MD, Perkins NJ, Whitcomb BW and Schisterman EF: Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 50: 419-430, 2008.
21. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
22. Yu SL, Chen HY, Chang GC, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57, 2008.
23. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
24. Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675, 2008.
25. Boeri M, Verri C, Conte D, et al: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 108: 3713-3718, 2011.
26. Wang GK, Zhu JQ, Zhang JT, et al: Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666, 2010.
27. Donaldson A, Natanek SA, Lewis A, et al: Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 68: 1140-1149, 2013.
28. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409, 2011.
29. Infante M, Cavuto S, Lutman FR, et al: A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 180: 445-453, 2009.
30. Shen J, Liu Z, Todd NW, et al: Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11: 374, 2011.
31. Cazzoli R, Buttitta F, Di Nicola M, et al: microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8: 1156-1162, 2013.